Lilly Oncology Medical· @LillyOncMed · X·· 2 天前评分70
正文 · 机器翻译
诚邀您参加 #ESMO2026，聆听关于 postMONARCH 3期试验总生存期的快速口头报告，该试验针对既往 CDK4/6i + ET 治疗后进展的 HR+, HER2- 晚期乳腺癌患者
1RO | 10月24日，上午10:59–11:04，Almeria Auditorium 9号厅
🔗https://e.lilly/4znE0mQ
#BreastCancer
195 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Lilly Oncology Medical · x.com